IONIS PHARMACEUTICALS INCIONS
| Dec 31, 2010 | Dec 31, 2011 | Dec 31, 2012 | Dec 31, 2013 | Dec 31, 2014 | Dec 31, 2015 | Dec 31, 2016 | Dec 31, 2017 | Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 |
---|
Cash and cash equivalents | 70 | 65 | 124 | 160 | 143 | 129 | 85 | 130 | 279 | 683 | 398 | 869 | 276 | 399 |
---|
Short-term investments | - | - | - | - | - | - | - | - | - | - | - | - | 1,710 | 1,932 |
---|
Contracts receivable | - | - | - | - | - | - | - | - | 13 | 63 | 76 | 62 | 26 | 98 |
---|
Inventories | - | - | - | - | - | - | - | - | 9 | 18 | 22 | 25 | 22 | 28 |
---|
Other current assets | 7 | 5 | 9 | 8 | 16 | 15 | 15 | 72 | 102 | 140 | 140 | 143 | 168 | 184 |
---|
Total current assets | 483 | 360 | 423 | 736 | 837 | 837 | 798 | 1,168 | 2,208 | 2,721 | 2,131 | 2,345 | 2,203 | 2,642 |
---|
Property, plant and equipment, net | 36 | 97 | 91 | 86 | 89 | 90 | 93 | 122 | 132 | 154 | 181 | 178 | 74 | 71 |
---|
Right-of-use assets | - | - | - | - | - | - | - | - | - | - | - | - | 182 | 172 |
---|
Deposits and other assets | - | - | - | - | - | - | - | 10 | 13 | 28 | 50 | 60 | 75 | 105 |
---|
Total assets | 550 | 485 | 546 | 847 | 956 | 956 | 912 | 1,322 | 2,668 | 3,233 | 2,390 | 2,612 | 2,534 | 2,990 |
---|
Accounts payable | 7 | 8 | 10 | 11 | 18 | 28 | 21 | 25 | 29 | 16 | 17 | 12 | 18 | 26 |
---|
Accrued compensation | 7 | 9 | 8 | 12 | 12 | 16 | 24 | 25 | 29 | 37 | 66 | 39 | 49 | 68 |
---|
Accrued liabilities | 12 | 19 | 15 | 22 | 30 | 28 | 36 | 67 | 48 | 67 | 90 | 89 | 140 | 148 |
---|
Income taxes payable | - | - | - | - | - | - | - | - | - | 33 | 1 | 0 | 6 | 2 |
---|
Current portion of deferred contract revenue | - | - | - | - | - | - | - | - | 160 | 118 | 108 | 98 | 91 | 151 |
---|
0.125 percent convertible senior notes, net | - | - | - | - | - | - | - | - | - | - | 293 | - | - | 44 |
---|
Other current liabilities | - | - | - | - | - | - | - | - | - | - | - | - | 8 | 9 |
---|
Current portion of deferred contract revenue | - | - | - | - | - | - | - | - | 160 | 118 | 108 | 98 | 91 | 151 |
---|
Total current liabilities | 106 | 76 | 74 | 98 | 115 | 149 | 134 | 225 | 280 | 273 | 583 | 241 | 312 | 448 |
---|
Other current liabilities | - | - | - | - | - | - | - | - | - | - | - | - | 8 | 9 |
---|
Total current liabilities | 106 | 76 | 74 | 98 | 115 | 149 | 134 | 225 | 280 | 273 | 583 | 241 | 312 | 448 |
---|
Long-term deferred contract revenue | - | - | - | - | - | - | - | - | 567 | 490 | 424 | 352 | 288 | 241 |
---|
0 percent convertible senior notes due April 2026. | - | - | - | - | - | - | - | - | - | - | - | 619 | 622 | 625 |
---|
1.75 percent convertible senior notes due June 2028. | - | - | - | - | - | - | - | - | - | - | - | - | - | 562 |
---|
0.125 percent convertible senior notes due December 2024. | - | - | - | - | - | - | - | - | - | 435 | 456 | 542 | 545 | - |
---|
0 percent convertible senior notes due April 2026. | - | - | - | - | - | - | - | - | - | - | - | 619 | 622 | 625 |
---|
0.125 percent convertible senior notes due December 2024. | - | - | - | - | - | - | - | - | - | 435 | 456 | 542 | 545 | - |
---|
Convertible senior notes, net | - | - | 144 | 150 | - | - | - | 533 | 568 | - | - | - | - | - |
---|
Long-term lease liabilities | - | - | - | - | - | - | - | - | - | - | - | - | 179 | 171 |
---|
Amount, after accumulated amortization, of the unamortized liability related to the sale of future royalties, pursuant to a royalty purchase agreement, that the Company is entitled to receive under collaboration agreements with Biogen and Novartis. The balance will be amortized over the estimated life of the arrangement using the effective interest rate method. | - | - | - | - | - | - | - | - | - | - | - | - | - | 514 |
---|
Long-term mortgage debt | - | - | - | - | - | - | - | 60 | 60 | 60 | 60 | 60 | 9 | 42 |
---|
Long-term lease liabilities | - | - | - | - | - | - | - | - | - | - | - | - | 179 | 171 |
---|
Long-term obligations | - | - | - | - | - | - | - | - | - | - | - | - | 7 | - |
---|
Long-term obligations | - | - | - | - | - | - | - | 60 | 60 | 60 | 60 | 60 | 9 | 42 |
---|
Total liabilities | 306 | 313 | 363 | 469 | 698 | 755 | 813 | 903 | 1,481 | 1,549 | 1,546 | 1,840 | 1,961 | 2,603 |
---|
Common stock, $0.001 par value; 300,000,000 shares authorized, 144,340,526 and 142,057,736 shares issued and outstanding at December 31, 2023 and December 31, 2022, respectively | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
---|
Additional paid-in capital | 1,000 | 1,014 | 1,077 | 1,325 | 1,225 | 1,309 | 1,311 | 1,550 | 2,047 | 2,204 | 2,114 | 1,964 | 2,060 | 2,215 |
---|
Accumulated other comprehensive loss | 1 | -1 | 12 | 21 | 40 | -14 | -30 | -32 | -32 | -25 | -21 | -33 | -57 | -33 |
---|
Accumulated deficit | -757 | -841 | -907 | -968 | -1,007 | -1,095 | -1,181 | -1,187 | -967 | -708 | -1,249 | -1,160 | -1,430 | -1,796 |
---|
Total stockholders' equity | 245 | 171 | 183 | 378 | 258 | 201 | 100 | 419 | 1,187 | 1,685 | 843 | 772 | 573 | 387 |
---|
Total liabilities and stockholders' equity | 550 | 485 | 546 | 847 | 956 | 956 | 912 | 1,322 | 2,668 | 3,233 | 2,390 | 2,612 | 2,534 | 2,990 |
---|